Table 1.
Characteristics of cases and controls.
| Study Characteristics | TB Case (n=23) | Control (n=32) | p-value | |
|---|---|---|---|---|
| Sex (n,%) | Male | 13 (56.5) | 13 (40.6) | 0.41 |
| Female | 10 (43.5) | 19 (59.4) | 0.41 | |
| Age (median, IQR) | 34 (31-41) | 35 (30.5-41) | 0.70 | |
| Baseline CD4 (median, IQR) | 32 (26-44) | 24.5 (14-37) | 0.53 | |
| Baseline HIV Log Viral Load (median, IQR) | 5.69 (5.24-6.22) | 5.41 (5.02-5.68) | 0.007 | |
| WHO Stage 3 or 4 (n,%) | 7 (30.87) | 7 (21.87) | 0.72 | |
| TB Therapy Arm (n,%) | Empiric 4-drug | 12 (52.17) | 16 (50) | 0.87 |
| IPT | 11 (47.83) | 16 (50) | 0.87 | |
| Time to TB Diagnosis in Weeks (median, IQR) | 4.6 (2-16.1) | — | ||
| Type of TB (n,%) | PTB | 12 (52.17) | — | |
| EPTB | 11 (47.83) | — | ||
| BMI < 18.5 kg/m2 (n,%) | 6 (26.09) | 5 (15.62) | 0.67 | |
| Albumin (median, IQR) | 3.55 (3.1-3.9) | 3.8 (3.4-4.3) | 0.015 | |
| Hemoglobin ≥ 8 μg/dL (n, %) | 21 (91.30) | 32 (100) | 0.09 | |
IQR, Interquartile range; WHO,World Health Organization; TB, Tuberculosis; IPT, Isoniazid preventative therapy; PTB, Pulmonary TB; EPTB, Extrapulmonary TB; BMI, Body Mass Index (BMI).